Management of Peyronie's Disease With Adipose Tissue Stem Cell

The Role of Adipose Tissue Stem Cell Injection Through Corpora Cavernosa and Intra Dorsal Penile Artery in Management of Erectile Dysfunction Associated With Peyronie's Disease

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02414308

Enrollment

Registered

2015-04-10

Start date

2013-06-30

Completion date

2016-07-31

Last updated

2015-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile Dysfunction, Peyronie' Disease

Keywords

Erectile dysfunction, Peyronie's disease, stem cell

Brief summary

Erectile dysfunction is growing in prevalence all over the world and one of the most existing disease in old age patients There is many lines of treatment concerning the status of patient like psychosexual, medical, and surgical treatment But Pyronie's disease is common now among people especially diabetics, and the role of treatment still controversial in results We can start conservative treatment and then surgical treatment if fail but the outcome still not convinced Many patients refuse to fix penile prosthesis and to make operation like nesbite for probability of shortening of penis We start to use stem cell in patients have erectile dysfunction and Peyronie's disease The injection of stem cell will be at corpora cavernosa and intra dorsal penile artery under Doppler device guidance

Detailed description

Peyronie's disease associated with erectile dysfunction nan be treated by different methods We start to treat such patients with adipose tissue stem cell Harvesting stem cell from adipose tissue and injected into corpora cavernosa and penile artery and we assess quality of erection through patient history and penile duplex and also assess plaque size and other symptoms related to Peyronie's disease

Interventions

DRUGAdipose tissue stem cell injection

Stem cell will be harvested through adipose tissue by liposuction and isolation occurred Injection will distribute through corpora cavernosa and dorsal penile artery

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Healthy volunteers

Yes

Inclusion criteria

* erectile dysfunction associated with Peyroni's diseas

Exclusion criteria

* nil

Design outcomes

Primary

Measure	Time frame	Description
sexual function questionnaire	2-3 months	Clinical history of patients before and after treatment Penile duplex study

Secondary

Measure	Time frame	Description
Penile plaque assessment	2-3 months	Clinical examination Patient history Penile duplex

Countries

Egypt

Contacts

Primary ContactKhaled A Gadalla, MD, ABS

Khaledgadalla@gmail.com20222725025

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026